TY - JOUR
T1 - Use of a Wearable EEG Headband as a Meditation Device for Women With Newly Diagnosed Breast Cancer
T2 - A Randomized Controlled Trial
AU - Millstine, Denise M.
AU - Bhagra, Anjali
AU - Jenkins, Sarah M.
AU - Croghan, Ivana T.
AU - Stan, Daniela L.
AU - Boughey, Judy C.
AU - Nguyen, Minh Doan T.
AU - Pruthi, Sandhya
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this study was received from the Ralph A. Stump & Radene G. Stump Foundation.
Publisher Copyright:
© The Author(s) 2019.
PY - 2019
Y1 - 2019
N2 - Background: Breast cancer diagnosis and treatment affect quality of life and stress and are associated with fatigue. Meditation interventions are effective strategies for patients with breast cancer but are often limited by poor access, high cost, substantial time commitment, and poor adherence. In this feasibility study, we investigated the use of a portable, wearable, electroencephalographic device for guided meditation practices by breast cancer patients during the period from breast cancer diagnosis until 3 months after surgical treatment. Methods: We enrolled women (age = 20-75 years) who had received a recent diagnosis of breast cancer and planned to undergo surgical treatment. Participants were randomly assigned to perform guided meditation with the device (intervention group) or receive CD-based stress-reduction education (control group). Surveys were used to measure stress, quality of life, and fatigue at baseline, within 4 days before surgery, up to 14 days after surgery, and at 3 months after surgery. Results: In the intervention group, 15 of 17 participants (88.2%) completed the study; in the control group, 13 of 13 participants completed the study (100%). Participants in both groups had less fatigue and stress and improved quality of life at 2 weeks and 3 months after surgery compared with baseline, but there were no significant intergroup differences at any time point. Conclusion: The use of this wearable electroencephalographic device for meditation is a feasible strategy for patients with breast cancer.
AB - Background: Breast cancer diagnosis and treatment affect quality of life and stress and are associated with fatigue. Meditation interventions are effective strategies for patients with breast cancer but are often limited by poor access, high cost, substantial time commitment, and poor adherence. In this feasibility study, we investigated the use of a portable, wearable, electroencephalographic device for guided meditation practices by breast cancer patients during the period from breast cancer diagnosis until 3 months after surgical treatment. Methods: We enrolled women (age = 20-75 years) who had received a recent diagnosis of breast cancer and planned to undergo surgical treatment. Participants were randomly assigned to perform guided meditation with the device (intervention group) or receive CD-based stress-reduction education (control group). Surveys were used to measure stress, quality of life, and fatigue at baseline, within 4 days before surgery, up to 14 days after surgery, and at 3 months after surgery. Results: In the intervention group, 15 of 17 participants (88.2%) completed the study; in the control group, 13 of 13 participants completed the study (100%). Participants in both groups had less fatigue and stress and improved quality of life at 2 weeks and 3 months after surgery compared with baseline, but there were no significant intergroup differences at any time point. Conclusion: The use of this wearable electroencephalographic device for meditation is a feasible strategy for patients with breast cancer.
KW - biofeedback
KW - breast cancer
KW - breast surgery
KW - fatigue
KW - integrative medicine
KW - meditation
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85072745661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072745661&partnerID=8YFLogxK
U2 - 10.1177/1534735419878770
DO - 10.1177/1534735419878770
M3 - Article
C2 - 31566031
AN - SCOPUS:85072745661
SN - 1534-7354
VL - 18
JO - Integrative Cancer Therapies
JF - Integrative Cancer Therapies
ER -